Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Free Cash Flow (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Free Cash Flow for 10 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 134.14% year-over-year to $5.5 million, compared with a TTM value of -$2.4 million through Dec 2025, up 96.51%, and an annual FY2025 reading of -$2.4 million, up 96.51% over the prior year.
  • Free Cash Flow was $5.5 million for Q4 2025 at Zevra Therapeutics, up from $4.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $16.6 million in Q2 2021 and bottomed at -$19.1 million in Q2 2024.
  • Average Free Cash Flow over 5 years is -$5.7 million, with a median of -$4.3 million recorded in 2022.
  • The sharpest move saw Free Cash Flow surged 654.71% in 2021, then plummeted 419.77% in 2022.
  • Year by year, Free Cash Flow stood at -$865000.0 in 2021, then tumbled by 419.77% to -$4.5 million in 2022, then plummeted by 260.99% to -$16.2 million in 2023, then dropped by 0.12% to -$16.2 million in 2024, then soared by 134.14% to $5.5 million in 2025.
  • Business Quant data shows Free Cash Flow for ZVRA at $5.5 million in Q4 2025, $4.2 million in Q3 2025, and -$3.8 million in Q2 2025.